Advanced Gastroenteropancreatic Neuroendocrine Tumors

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.